Oxetacaine Ip - Pharmaceutical Compound Compliant With Ip Monograph | Local Anesthetic And Antacid, Quality Assured, Microbial Limits Ensured

Key specifications outlined in the IP monograph for Oxetacaine typically include:

Identification: Methods to confirm the presence and purity of Oxetacaine, ensuring it meets defined standards without contamination.

Assay: Quantitative determination of the potency of Oxetacaine, usually expressed as a percentage of the labeled amount, ensuring consistent local anesthetic action.

Related Substances: Limits on impurities and degradation products to maintain purity and safety.

Residual Solvents: Maximum allowable levels of solvents used in manufacturing, ensuring the final product is free from harmful residues.

Loss on Drying: Measurement of moisture content to prevent degradation and ensure stability throughout storage and use.

Heavy Metals: Strict limits on toxic heavy metals such as lead, arsenic, mercury, and cadmium to ensure product safety.

Microbial Limits: Specifications ensuring the absence of harmful microorganisms, maintaining microbiological purity.

Particle Size Distribution: Requirements for particle size uniformity to optimize formulation stability and effectiveness.

Uniformity of Dosage Units: Criteria ensuring consistent dosage across individual formulations (e.g., gels, suspensions).

Packaging: Specifications for materials and labeling that preserve the integrity and stability of Oxetacaine during storage and distribution.